CN107281098A - A kind of hemofiltration replacement liquid - Google Patents

A kind of hemofiltration replacement liquid Download PDF

Info

Publication number
CN107281098A
CN107281098A CN201710518920.6A CN201710518920A CN107281098A CN 107281098 A CN107281098 A CN 107281098A CN 201710518920 A CN201710518920 A CN 201710518920A CN 107281098 A CN107281098 A CN 107281098A
Authority
CN
China
Prior art keywords
replacement liquid
hemofiltration replacement
hemofiltration
phosphate
citrate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201710518920.6A
Other languages
Chinese (zh)
Inventor
沈圣民
王刚
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Huaren Pharmaceutical Co Ltd
Original Assignee
Huaren Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Huaren Pharmaceutical Co Ltd filed Critical Huaren Pharmaceutical Co Ltd
Priority to CN201710518920.6A priority Critical patent/CN107281098A/en
Publication of CN107281098A publication Critical patent/CN107281098A/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
    • A61J1/05—Containers specially adapted for medical or pharmaceutical purposes for collecting, storing or administering blood, plasma or medical fluids ; Infusion or perfusion containers
    • A61J1/10—Bag-type containers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/42—Phosphorus; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions

Abstract

Present invention offer is a kind of to be realized partially anti-freezing function, corrects acid poisoning, the hemofiltration replacement liquid of reduction hypophosphatemia generation, belongs to medical medicine preparation technique field.The each group for the hemofiltration replacement liquid that the present invention is provided is divided into：75~160mmol/L of electrolyte, 0.5~3.0mmol/L of citrate, NaHCO310~40mmol/L, 0~2mmol/L of phosphate, 0~2g/L of DEXTROSE ANHYDROUS, 1~20mmol/L of buffer, 0~100mmol/L of therapeutic component.The present invention also provides the mixed pH value of liquid of the Room of packaged form A, B two for the dual-chamber bag that hemofiltration replacement liquid uses A, B dual chamber for 6.0~8.0.Hemofiltration replacement liquid packaging bag of the present invention is made up of non-PVC material.Using instant component hemofiltration replacement liquid safely, effectively, with obvious generalization.

Description

A kind of hemofiltration replacement liquid
Technical field
The present invention relates to the hemofiltration replacement liquid that a kind of kidney patients use, belong to medical medicine Reagents Drugs technology neck Domain.
Background technology
Continuous renal replacementtherapy (CRRT) is initially mainly used in treatment acute renal failure (ARF), by research Explore, constantly deepen with the understanding of CRRT mechanism of action, its application is also gradually expanded.Such as CRRT technologies are more Plant to have in the treatment of critical illness and constantly remove toxin, effectively control water, salt metabolism, stable haemodynamics ensures nutrition The effect such as support and intravenous pharmacy treatment；Good homeostasis is provided for the treatment of critical patient, so as to reach promotion disease Feelings are recovered, and improve treatment success rate.
When clinic carries out CRRT treatments, it is necessary to which supplemental blood filters displacement liquid, to reach the mesh of fluid balance in patient's body 's.Presently commercially available hemofiltration replacement liquid is main based on lactic acid salt form.CRRT is carried out using lactate as buffer solution to control Treat, the effect that it corrects metabolic acidosis is similar to bicarbonate.But many urgent patients are often accompanied by lactic acidosis, liver function Can infringement, hypoxemia and metabolic disorder, the ability reduction of organism metabolism lactic acid, it is impossible to be resistant to a large amount of lactate blood filterings and put The input of liquid is changed, acid poisoning is even resulted in or aggravate.By contrast, bicarbonate salt form hemofiltration replacement liquid is commonly used in the world, Realized in the case where not increasing burden of liver and correct metabolic acidosis；The complication and pair during treatment can also be reduced simultaneously Effect.Reported such as BARENBROCK, using the case fatality rate of bicarbonate and lactate buffer patient without aobvious in CRRT Difference is write, but bicarbonate group cardiovascular event risk substantially lowers, and is more suitable for CRRT.Bicarbonate salt form hemofiltration replacement liquid Maximum preparation difficult point is, bicarbonate easily reacts generation insoluble precipitate with the inorganic ion such as calcium, magnesium, so that Influence the stability of preparation.This is also the principal element that the domestic pharmacy corporation of limitation develops this product.
The use of anti-coagulants is essential to CRRT treatment.At present clinically conventional anti-coagulants mainly have heparin and Its derivative, sodium citrate and new anti-coagulants hirudin etc..But when patient has active hemorrhage, or the related blood of heparin Platelet reduces situation, is forbidden using anticoagulant heparin method.Citric acid trisodium (trisodium citrate, sodium citrate) There is partially anti-freezing function.In recent years, in blood purification treatment, especially in the patient that heparin or other anti-coagulants are avoided Apply.Sodium citrate reduces serum ion calcium concentration, and then blocked Blood Coagulation Process by complexing calcium ions.And This effect is reversible, as long as adding enough calcium ions, coagulation function then can recover normal immediately.Sodium citrate enters After in vivo, tricarboxylic acid cycle mainly is participated in liver and musculature and cortex renis, sodium acid carbonate (per molecule is metabolized as quickly Metabolizable sodium citrate is three molecule sodium acid carbonates), it also can efficiently correct the metabolic acidosis of patient with severe symptoms.With heparin phase Than, sodium citrate energy partially anti-freezing function, and good biocompatibility, the related leucocyte of no-rod tractor, blood platelet reduction；Reduce calcium from While having the effect for correcting acid poisoning, therefore it is a kind of ideal anti-coagulants after son.
CRRT treatments can cause patient body fluid P elements to be lost often.Because CRRT is high to phosphatic elimination efficiency, and Commercially available hemofiltration replacement liquid is not usually phosphorous, therefore the incidence of patient's hypophosphatemia is higher, has statistics to think low-phosphorous The incidence of mass formed by blood stasis is up to 17.6%~65.1%.Therefore supplement phosphorus need to be taken the circumstances into consideration when carrying out CRRT treatments.
The content of the invention
The present invention is intended to provide the good correction metabolic acidosis of a kind of achievable partially anti-freezing function, tool and supplement CRRT are controlled Treat the hemofiltration replacement liquid of the effects such as the phosphate of loss.
In order to solve the above-mentioned technical problem, mainly realized by the following technical programs.
A kind of hemofiltration replacement liquid includes following components：
Specifically, electrolyte of the invention is one or more in sodium salt, sylvite, calcium salt, magnesium salts or chloride ion-containing salt.
Preferably, electrolyte components are the one or more in sodium chloride, potassium chloride or magnesium chloride.
Specifically, above-mentioned citrate is sodium citrate or potassium citrate.It is preferred that, the addition of citrate is 0.5 ~1.5mmol/L.
Specifically, the preferred scope of sodium acid carbonate is 24~32mmol/L.
Specifically, above-mentioned phosphate is sodium phosphate, disodium hydrogen phosphate, sodium dihydrogen phosphate, potassium phosphate, dipotassium hydrogen phosphate or phosphorus Any one or a few in acid dihydride potassium.It is preferred that, phosphate addition scope is 1.0~1.5mmol/L.
Specifically, the preferred scope of above-mentioned DEXTROSE ANHYDROUS is 0.5~1.2mmol/l.
Specifically, above-mentioned buffer is bicarbonate, citrate, isocitrate, phosphate, lactate, pyruvic acid Salt, succinate, fumarate, malate or oxaloacetate；It is preferred that, buffer be citrate, phosphate or Bicarbonate.
Specifically, hemofiltration replacement of the invention also such as vasodilator, diuretics, hormone, dimension containing curative drug Raw element, antioxidant etc..
Present invention also offers the packing method of hemofiltration replacement liquid, it uses the packaged form of dual-chamber bag.
Specifically, the packaging bag of hemofiltration replacement liquid is divided into the Room of A, B two, and wherein A rooms include electrolyte and glucose, B Room includes electrolyte, phosphate, buffer, citrate.After the mixing of A, B room, the blood filtering that can be achieved close to physiological pH is put Change liquid.
It can realize that bicarbonate and calcium, magnesium salts are effectively isolated by the way that preparation packaging bag is set into dual-chamber bag, strengthen The compatibility stability of preparation；Because phosphate, buffer, citrate belong to strong base-weak acid salt, with potential unstable Property, therefore three is placed in same room, pH value is adjusted to alkalescence to strengthen its stability.
Specifically, the mixed pH value of A, B liquid of hemofiltration replacement liquid is 6.0~8.0.It is preferred that hemofiltration replacement liquid The mixed pH value of A, B liquid be 6.4~7.0.
Citrate is added in the hemofiltration replacement liquid of the present invention, to realize external partially anti-freezing function during CRRT treatments, It is particularly suitable for the patient for having hemorrhagic tendency.Sodium citrate produces bicarbonate after organism metabolism simultaneously, so as to further play Correct the effect of metabolic acidosis.Bicarbonate is substituted to conventional lactate in prescription, good correction acid can be played Poisoning, while reducing the related adverse reaction of high lactic acid.In addition, newly adding phosphate, especially disodium hydrogen phosphate can be effective Make up the phosphorus caused during CRRT treatments to lose, reduce the incidence of hypophosphatemia.
In terms of drug effect realization, sodium citrate is added in hemofiltration replacement liquid, the mode diluted in the past participates in blood Filtering therapy, can effectively realize external partially anti-freezing function blood effect, while being entangled into metabolizable played for bicarbonate after body The effect of positive metabolic acidosis.
The packaging bag of hemofiltration replacement liquid of the present invention uses polypropylene, polyethylene, polyvinyl chloride, polyester, ethene/acetic acid One or more of compositions are prepared from vinyl ester copolymers, styrene-ethylene-butadiene (SEB polymer) or nylon.
Beneficial effect
Replace lactate as buffer system using bicarbonate in blood replacing liquid component of the present invention, lactic acid can be avoided a large amount of The side effect that input tape comes, while preferably correcting acid poisoning.In addition, adding phosphate, patient can be effectively supplemented in CRRT The phosphorus caused during treatment is lost, and reduces the generation of hypophosphatemia.Therefore preparation and formula mentality of designing more than, it is final to prepare Go out the hemofiltration replacement liquid with more preferable drug action.
Sodium citrate is added in the New Blood filtration displacement liquid of the present invention, is resisted with external part when realizing CRRT treatments It is solidifying, it is particularly suitable for the patient for having hemorrhagic tendency.And sodium citrate produces bicarbonate after organism metabolism, can further it play Correct the effect of metabolic acidosis.
When the present invention is by the packaging of hemofiltration replacement liquid, using double-chamber structure, it is to avoid precipitation is produced, enhancing compatibility is steady It is qualitative, while the filtered solution pH finally obtained is close to biological value, reduce potential safety hazard.Hemofiltration replacement liquid packaging bag of the present invention Using non-PVC material, enhancing Clinical practice safety.
Brief description of the drawings
The mean survival time result figure of each example of Fig. 1 present invention.
The ultrafiltration volume result of each example of Fig. 2 present invention.
The serium inorganic phosphorus result of each example of Fig. 3 present invention.
Embodiment
Technical scheme is further elaborated below by way of with embodiment, wherein involved occurrence, Parameter Conditions are not as a limitation of the invention.Those skilled in the art are on the basis of technical scheme is understood, that is done is any Improve and change belongs to protection scope of the present invention.
Specific embodiment then according to the novel hydrocarbonate hemofiltration replacement liquid composition compositing range containing sodium citrate, 6 embodiments are devised, specific prescription is as shown in table 1.
Each embodiment composition of table 1 (the mixed final concentration of A, B liquid)
Each embodiment A, the B room of table 2 prepares volume and its pH value
Embodiment A building volumes (ml) B building volumes (ml) A rooms pH value B rooms pH value
Example 1 600 1400 2.8 9.0
Example 2 720 1280 3.0 8.5
Example 3 800 1200 3.2 8.2
Example 4 1000 1000 3.5 8.0
Example 5 1280 720 3.8 7.5
Example 6 1400 600 4.0 7.0
Preparation method：
It is standby that three layers of transfusion co-extrusion film dual-chamber bag are prepared first.Appropriate water for injection is taken, bulk drug such as chlorination is put into Magnesium, calcium chloride and glucose, fully dissolving, constant volume are inserted in A rooms after adjusting pH value, miillpore filter refined filtration.Take appropriate injection With water, input bulk drug such as sodium chloride, potassium chloride, disodium hydrogen phosphate, sodium acid carbonate, sodium citrate fully dissolve, constant volume, regulation PH value, miillpore filter refined filtration is subsequently placed in B rooms.Sterilized (moist heat sterilization, 121 DEG C of sterilising temp, sterilization time after embedding 15min), that is, finished product is obtained.
More than the sample of throwing of each example carried out according to the composition of table 1, table 2 so that after the Room of A, B two is well mixed, respectively into The final concentration divided meets the description of table 1.
Each example pharmacodynamic experiment
(1) to the therapeutic action of acute liver failure
1st, dog acute hepatic failure model is set up
Healthy adult male beagle dogs 35, body weight is randomly divided into randomized controlled treatment group (n=5) and each reality in 12~15kg Shi Li treatment groups (each embodiment n=5, altogether 30).30% paracetamol (0.5ml/kg) is injected intravenously for the first time, While the carbon tetrachloride of abdominal part hypodermic 40% (0.5ml/kg).Repeat administration after 12nd hour, medication ibid, but dosage Halve.It thereby establish dog acute hepatic failure model.Each group animal gives Hemofiltration for Treatment in 24 hours upon administration.
2nd, Hemofiltration for Treatment
All animals use femoral artery and femoral vein indwelling single-chamber ductus venosus.Using the special filtration blood vessel of BM25 children Road, using the spy's BM25 bedside filtering machines of the U.S. hundred, blood pump maintains CBF to be 50ml/min.Using German Fresenius (membrane area is 0.7m to AV400 PS membranes transfusion filters2, 220 μm of film internal diameter, ultrafiltrate coefficient 250ml/h).It is divided into 7 examinations Group (every group of n=5) is tested, wherein randomized controlled treatment group gives commercially available lactate hemofiltration replacement liquid treatment (composition composition：Every liter Containing sodium chloride 5.92g, potassium chloride 0.149g, calcium chloride dihydrate 0.276g, sodium lactate 3.78g, magnesium chloride hexahydrate 0.152g and Dextrose Monohydrate 1.5g, wherein not potassium-containing hydrogen salt, citrate and phosphate), remaining each each one group of implementation of correspondence of example Example treatment group, every group of 5 dogs.By each group displacement liquid according to preceding dilution method, inputted with 500ml/h speed, go out ultrafiltration volume according to The loop condition of dog is adjusted.
Wherein, control group uses heparin method anti-freezing, i.e., be persistently pumped into using LMWHs (20U/kgh).It is each to implement Example group realizes external partially anti-freezing function with the sodium citrate contained in its displacement liquid.
3rd, experimental result
(1) life span compares
The mean survival time of each embodiment (ties apparently higher than the control group using traditional lactate hemofiltration replacement liquid Fruit is as shown in Figure 1).
(2) to the improvement result of liver function index
The serum after each group dog is only treated before modeling, after Cheng Mo and into mould is collected respectively, detects its liver function index ALT and AST.Each group numerical value is as shown in table 3.(table 3 is located on horizontal paper)
Liver function is in range of normal value before the modeling of each group beasle dog, and ALT and AST steeply rises after modeling 24 hours, Acute liver failure occurs for prompting.After control group Hemofiltration for Treatment, ALT and AST are decreased obviously, and are illustrated to hepatic failure With good therapeutic action.After the treatment of example 1-6 treatment groups, ALT and AST are remarkably decreased compared with pre-treatment, and it is counted Value is less than control group.Illustrate that each example prepared is better than control group to the curative effect of hepatic failure.
(3) to the therapeutic action of hyperlactacidemia
The major organs that body removes lactic acid in blood are livers, next to that kidney and skeletal muscle, cardiac muscle.It is acute when occurring During liver failure, often there is hyperlactacidemia.For example in this experiment, serum breast after drug-induced acute liver failure The concentration of acid is significantly raised.Now, carried out using the conventional blood filtration displacement liquid containing lactic acid after Hemofiltration for Treatment, due to Excessive lactic acid enters in the blood circulation of dog, causes lactic acid in blood to sharply increase, there occurs hyperlactacidemia.When using being free of After the example 1-6 of lactic acid, its each group lactic acid concn has declined.Detailed results are shown in Table 3.
It these results suggest that each example is more applicable for the body that there is hepatosis, and with certain correction breast The effect of sour acid poisoning.
(4) to the influence of coagulation function
Because antithrombins material is mainly synthesized by liver, when occurring acute hepatic function damage, blood coagulation work(is often accompanied by Can obstacle.For example, each group beasle dog is after drug-induced acute liver damage in this experiment, International standardization prothrombin time ratio Value (INR) substantially increases, and points out the clotting time to extend.When using traditional lactate blood filtering liquid, heparin is employed Anticoagulant methods, as a result find that further increase occurs for its INR numerical value after treatment, points out the tendency with bleeding.And use Chinese holly The example 1-6 each groups of the external anti-freezing of same regimen acid salt, its INR does not increase after treatment, on the contrary with downward trend.Illustrate pair In there is the situation of blood coagulation disorders, each example is safer using the external anti-freezing of citrate.
Each experimental study is confirmed above：The hemofiltration replacement liquid of the present invention, due to without lactic acid, and uses citrate External anti-freezing, compared to traditional lactate hemofiltration replacement liquid, is more applicable for liver function damage, has the feelings of hemorrhagic tendency Shape.
(2) to the therapeutic action of acute renal failure
1st, prepared by acute renal failure animal model
Healthy male beagle dogs 35,10~15kg of body weight.Anesthesia：Preoperative night is fasted.3% amobarbital (30~ 45) mg/kg intraperitoneal injection of anesthesia.Under sterile working (including cleaning animal, preserved skin, routine disinfection, drape), in taking, lower abdomen 6~10cm of median incision, opens abdominal cavity, and bilateral ureteral is ligatured with No. 4 silk threads.Successively close abdominal cavity.It is last in femoral artery, it is quiet Arteries and veins inlying catheter, as detection mean arterial pressure, extracts sample, Hemofiltration for Treatment etc..Terminate dynamic to off-test from operation The equal fasting of thing, gives venous transfusion maintenance.All animals give 5% glucose 200ml, 10% chlorination by per kilogram of body weight daily Sodium 5.0ml, 10% potassium chloride 2.5ml and vitamin C 0.25g.Ligature bilateral ureteral after 12h, anaesthetize again, after anesthesia on Lung ventilator (U.S.'s PB-1001 types), using assisted ventilation (A/C) pattern, tidal volume 200ml, machine control frequency is 12 times/min, is inhaled Oxygen concentration (FiO2) it is 21%.
2nd, Hemofiltration for Treatment
All animals use femoral artery and femoral vein indwelling single-chamber ductus venosus.Using the special filtration blood vessel of BM25 children Road, using the spy's BM25 bedside filtering machines of the U.S. hundred, blood pump maintains CBF to be 50ml/min.Using German Fresenius (membrane area is 0.7m to AV400 PS membranes transfusion filters2, 220 μm of film internal diameter, ultrafiltrate coefficient 250ml/h).It is divided into 7 examinations Group is tested, wherein (composition is constituted by control group of commercially available lactate hemofiltration replacement liquid：Every liter contains sodium chloride 5.92g, chlorine Change potassium 0.149g, calcium chloride dihydrate 0.276g, sodium lactate 3.78g, magnesium chloride hexahydrate 0.152g and Dextrose Monohydrate 1.5g, wherein Not potassium-containing hydrogen salt, citrate and phosphate), remaining each each one group of correspondence of example, every group of 5 dogs.By each group displacement liquid According to preceding dilution method, inputted with 500ml/h speed, go out ultrafiltration volume and be adjusted according to the loop condition of dog.
Wherein, control group uses heparin method anti-freezing, i.e., be persistently pumped into using LMWHs (20U/kgh).It is each to implement Example group realizes external partially anti-freezing function with the sodium citrate contained in its displacement liquid.
3rd, experimental result
(1) anticoagulant effect is observed
It is observed that all experimental animals situation in treatment whole process is stable, no death incident occurs.Transfusion filters Tool does not occur blood coagulation in treatment end.After treatment end, all animals also do not occur bleeding episode.This result illustrates this hair Bright prepared hemofiltration replacement liquid has good external partially anti-freezing function effect.
(2) ultrafiltration volume and small molecule Solute removal result
Ultrafiltration result is as shown in Fig. 2 when each example carries out Hemofiltration for Treatment, can realize good ultrafiltration.Respectively Ultrafiltration volume difference between example is not obvious, difference that there are no significant compared with control group.Maintain good ultrafiltration simultaneously, It is also fairly obvious to the removing such as serum creatinine, blood urea nitrogen of small molecule, as shown in table 4.(table 4 is located on the horizontal paper of nextpage) is each The blood filtering experiment that example is participated in is consistent with control group, can significantly realize the scavenging action to creatinine and urea nitrogen.
(3) acid-base balance changes
Each example can effectively reverse the metabolic acidosis caused by acute renal failure after blood filter treatment.Its In, the error-correcting effect of each example set is better than control group, illustrates that each example can efficiently correct metabolic acidosis.As a result such as table Shown in 4.
(4) phosphate supplementary function
Each group collects blood, detects serium inorganic phosphorus index when blood filters treatment end.As a result as shown in figure 3, control group is treated Afterwards, occurs hypophosphatemia (average value is 0.68mmol/L).In each example set, 2 groups of example due to not phosphate-containing in formula, its Serium inorganic phosphorus value is similar to control group.Remaining each example set serium inorganic phosphorus value is apparently higher than control group, the scope in normal serium inorganic phosphorus.Tie above Fruit is pointed out, and traditional lactate hemofiltration replacement liquid can cause the loss of phosphoric acid in Hemofiltration for Treatment, cause hypophosphatemia. The present invention increases phosphate in formula, has phosphatic supplementary function during treatment, is prevented effectively from the generation of hypophosphatemia.
Explanation is tested above：The hemofiltration replacement liquid of the present invention is used to treat acute renal failure, not only with good Good external anti-freezing, ultrafiltration and the scavenging action of small molecule solute.And there is preferably correction acid poisoning compared to traditional product With the phosphatic curative effect of supplement.
The each group serum biochemistry of table 3 and to INR influence result (numerical value withRepresent)
Continuous upper table
Each example of table 4. to small molecule remove and acid-base balance result of the test (numerical value withRepresent, unit：mmol/L)
Continuous upper table

Claims (10)

1. a kind of hemofiltration replacement liquid, it is characterised in that：Including following components：
2. a kind of hemofiltration replacement liquid according to claim 1, it is characterised in that：Including following components：
3. a kind of hemofiltration replacement liquid according to claim 1, it is characterised in that：The electrolyte be sodium salt, sylvite, It is one or more of in calcium salt, magnesium salts or chloride ion-containing salt.
4. a kind of hemofiltration replacement liquid according to claim 1, it is characterised in that：The electrolyte is sodium chloride, chlorine Change the one or more in potassium or magnesium chloride.
5. a kind of hemofiltration replacement liquid according to claim 1, it is characterised in that：The citrate is sodium citrate Or potassium citrate.
6. a kind of hemofiltration replacement liquid according to claim 1, it is characterised in that：The phosphate is sodium phosphate, phosphorus Any one or a few in sour disodium hydrogen, sodium dihydrogen phosphate, potassium phosphate, dipotassium hydrogen phosphate or potassium dihydrogen phosphate.
7. a kind of hemofiltration replacement liquid according to claim 1, it is characterised in that：The buffer be bicarbonate, Citrate, isocitrate, phosphate, lactate, acetonate, succinate, fumarate, malate or oxalyl Acetate.
8. a kind of hemofiltration replacement liquid according to claim 1, it is characterised in that：The hemofiltration replacement liquid is also wrapped Containing vasodilator, diuretics, hormone, vitamin or anti-oxidant.
9. a kind of packing method of hemofiltration replacement liquid described in claim 1~8, it is characterised in that：Using A, B dual chamber The packaged form of dual-chamber bag, A rooms include electrolyte and glucose, and B rooms include phosphate, buffer, citrate, the Room of A, B two The mixed pH value of liquid be 6.0~8.0.
10. a kind of packaging bag of hemofiltration replacement liquid described in claim 1~8, it is characterised in that：It is by polypropylene, poly- One or more of systems in ethene, polyvinyl chloride, polyester, ethylene/vinyl acetate copolymer, styrene-ethylene-butadiene or nylon It is standby to form.
CN201710518920.6A 2017-06-30 2017-06-30 A kind of hemofiltration replacement liquid Pending CN107281098A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201710518920.6A CN107281098A (en) 2017-06-30 2017-06-30 A kind of hemofiltration replacement liquid

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201710518920.6A CN107281098A (en) 2017-06-30 2017-06-30 A kind of hemofiltration replacement liquid

Publications (1)

Publication Number Publication Date
CN107281098A true CN107281098A (en) 2017-10-24

Family

ID=60099883

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201710518920.6A Pending CN107281098A (en) 2017-06-30 2017-06-30 A kind of hemofiltration replacement liquid

Country Status (1)

Country Link
CN (1) CN107281098A (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112426359A (en) * 2020-11-30 2021-03-02 山东齐都药业有限公司 Double-chamber bag sugar-containing ringer's solution and preparation method thereof

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1280830A (en) * 2000-03-31 2001-01-24 广州医学院第二附属医院 Soft package type enclosed hemodialysis liquid, its special package bag and its application
CN1328467A (en) * 1998-10-20 2001-12-26 高级肾脏技术公司 Buffered composition for dialysis
CN1717258A (en) * 2003-02-04 2006-01-04 弗雷森纽斯医疗护理德国有限责任公司 Bicompartment bags for haemodyalisis machines and a process for manufacturing them
CN101254316A (en) * 2007-12-04 2008-09-03 中国人民解放军第二军医大学 Blood filtering replacement liquid prescription special for anti congealing
CN103432164A (en) * 2013-09-11 2013-12-11 华仁药业股份有限公司 Peritoneal dialysis solution and preparation method thereof
CN103816182A (en) * 2014-02-26 2014-05-28 四川大学华西医院 Hemofiltration solution and preparation method thereof
CN204709392U (en) * 2015-05-25 2015-10-21 华仁药业股份有限公司 A kind of powder and liquid double-chamber bag for hemofiltration replacement liquid

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1328467A (en) * 1998-10-20 2001-12-26 高级肾脏技术公司 Buffered composition for dialysis
CN1280830A (en) * 2000-03-31 2001-01-24 广州医学院第二附属医院 Soft package type enclosed hemodialysis liquid, its special package bag and its application
CN1717258A (en) * 2003-02-04 2006-01-04 弗雷森纽斯医疗护理德国有限责任公司 Bicompartment bags for haemodyalisis machines and a process for manufacturing them
CN101254316A (en) * 2007-12-04 2008-09-03 中国人民解放军第二军医大学 Blood filtering replacement liquid prescription special for anti congealing
CN103432164A (en) * 2013-09-11 2013-12-11 华仁药业股份有限公司 Peritoneal dialysis solution and preparation method thereof
CN103816182A (en) * 2014-02-26 2014-05-28 四川大学华西医院 Hemofiltration solution and preparation method thereof
CN204709392U (en) * 2015-05-25 2015-10-21 华仁药业股份有限公司 A kind of powder and liquid double-chamber bag for hemofiltration replacement liquid

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112426359A (en) * 2020-11-30 2021-03-02 山东齐都药业有限公司 Double-chamber bag sugar-containing ringer's solution and preparation method thereof

Similar Documents

Publication Publication Date Title
KR101813740B1 (en) Dialysis precursor composition
EP1465688B9 (en) Bicarbonate-based solutions for dialysis therapies
EP1753437B1 (en) Bicarbonate-based peritoneal dialysis solutions
KR101831007B1 (en) Dialysis precursor composition
US10709833B2 (en) Multipart fluid system and a system for regional citrate anticoagulation in an extracorporeal blood circuit
AU2008307966B2 (en) Stable bicarbonate ion-containing drug solution
US7053059B2 (en) Dialysis solutions with reduced levels of glucose degradation products
WO1993021935A1 (en) Preparation and method for production of platelet concentrates with significantly prolonged viability during storage
KR20050089833A (en) Biocompatible dialysis fluids containing icodextrins
MXPA00011216A (en) Novel pharmaceutical composition for use in emergency treatment and preparation method thereof.
EP1176969A2 (en) Substitution infusion fluid and citrate anticoagulation
CN107281098A (en) A kind of hemofiltration replacement liquid
KR102257246B1 (en) An anticoagulation fluid comprising citrate and phosphate
CN108310005A (en) A kind of peritoneal dialysis solution for resisting fibration of peritonaeum
CN103932981A (en) Heparin sodium tube-sealing injection
CN111603479A (en) Blood purification concentrate
CN115811988A (en) Blood purification molecule concentrate and preparation method and application thereof
US20040022816A1 (en) Fluid for haemofiltration
EP1897535A1 (en) Substitution fluid for haemofiltration
CN100361706C (en) Expanding diuretic for treating pulmonary edema in perioperative period of hepatic and biliary diseases
Dolbec Peritoneal dialysis
WO2013026118A1 (en) Ready-to-use electrolyte formulation, ready-to-use bag, kit, uses and method for treating kidney failure

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20171024

RJ01 Rejection of invention patent application after publication